Table (E)T-1: Demographic data
Patient no. / Age, y/sex/H&Y stage(“on”–“off” medication)* / Duration of disease (years) / PD treatment
(total dose/day)** / Time since stereotactic surgery (months) / Stimulus parameter
(contacts, voltage, pulse width, frequency)***
1 / 51/F/2-3 / 16 / L-DOPA 900mg,
amantadine 300mg / 4 / R: 3-Case+, 2.8 V, 60 µs, 130 Hz
L: 3-Case+, 2.6 V, 60 µs, 130 Hz
2 / 63/M/3-4 / 28 / L-DOPA 1150mg,
entacapone 1200mg / 31 / R: 0-Case+, 3.1 V, 60 µs, 130 Hz
L: 2-Case+, 2.6 V, 60 µs, 130Hz
3 / 48/F/3-4 / 17 / L-DOPA 1050mg,
entacapone 800mg / 25 / R: 0-Case+, 3.6 V, 60 µs, 130 Hz
L: 2-Case+, 3.6 V, 90 µs, 185 Hz
4 / 57/M/2,5-3 / 17 / L-DOPA 500mg, amantadine 200mg, selegiline 10mg / 17 / R: 1-Case+, 2.0 V, 60 µs, 130 Hz
L: 1-Case+, 3.3 V, 60 µs, 160 Hz
5 / 65/M/2-3 / 13 / L-DOPA 600mg,
pergolide 3mg / 17 / R: 2-Case+, 3.5 V, 90 µs, 130 Hz
L: 0-Case+, 3.5 V, 60 µs, 130 Hz
6 / 51/F/2-3 / 15 / L-DOPA 425mg, cabergoline 3mg, amantadine 400mg / 24 / R: 0-Case+, 2.0 V, 60 µs, 130 Hz
L: 3-Case+, 2.4 V, 60 µs, 130 Hz
7 / 79/M/3-4 / 20 / L-DOPA 900mg / 12 / R: 2-Case+, 3.1 V, 60 µs, 130 Hz
L: 2-Case+, 2.9 V, 60 µs, 130 Hz
8 / 60/F/3-4 / 19 / L-DOPA 650mg,
amantadine 200mg / 36 / R: 2-Case+, 2.1 V, 60 µs, 185 Hz
L: 3-Case+, 2.8 V, 60 µs, 185 Hz
* H&Y = Hoehn and Yahr Rating Scale, assessed with stimulators turned “on”
** L-DOPA = regular + controlled-release L-DOPA (with a peripheral decarboxylase inhibitor)
*** R = right STN, L = left STN, STN = Subthalamic Nucleus
Contact address: